Tanada S, Takashima E, Haruta T, Kobayashi Y
Jpn J Antibiot. 1985 May;38(5):1279-86.
Human pharmacokinetics and clinical studies of cefminox (CMNX, MT-141) were carried out and the following results were obtained. The concentrations of CMNX transferred to the uterus and its appendages after CMNX 1 g intravenous injection were maintained above 12.5 micrograms/g during first 3 hours or more. The concentrations of CMNX transferred to the pelvic dead space exudate were above 12.5 micrograms/ml during 6 hours or more. Those concentrations were sufficiently effective against the major pathogens (Gram-negative and anaerobic bacteria) demonstrated in the field of obstetrics and gynecology. We administered CMNX to 4 cases with postoperative infections at a dose of 2 g per day (twice a day) for a period of 4-6 days. The clinical effect was excellent in 3, good in 1 case. No side effect was observed.
进行了头孢米诺（CMNX，MT - 141）的人体药代动力学和临床研究，获得以下结果。静脉注射1g头孢米诺后，头孢米诺转移至子宫及其附件的浓度在最初3小时或更长时间内维持在12.5微克/克以上。头孢米诺转移至盆腔死腔渗出液中的浓度在6小时或更长时间内高于12.5微克/毫升。这些浓度对妇产科领域中显示的主要病原体（革兰氏阴性菌和厌氧菌）具有足够的效力。我们对4例术后感染患者给予头孢米诺，剂量为每天2g（每日两次），持续4 - 6天。临床效果3例为优，1例为良。未观察到副作用。
